AC Immune SA reported a net loss of CHF 23,270 thousand, or CHF 0.25 per share, for the second quarter ended June 30, 2025. The company's revenue for the period was CHF 1,400 thousand, missing analyst estimates.
Despite the financial results, AC Immune highlighted continued progress in its clinical pipeline. Interim results on ACI-7104.056, its wholly owned alpha-synuclein active immunotherapy, reinforced its best-in-class characteristics with strong immunogenicity and a favorable safety profile in early Parkinson’s disease.
The company's partnered programs, ACI-24.060 and ACI-35.030, are progressing according to plan. A significant early-stage development is that ACI-19764, a novel Morphomer small molecule inhibitor of NLRP3, has entered Investigational New Drug (IND)-enabling studies.
AC Immune maintains a strong cash position, providing funding into 2027, excluding potential milestone payments. Upcoming milestones for 2025 include further interim results from Part 1 of the VacSYn trial of ACI-7104.056 and the AD3 cohort in the ABATE trial of ACI-24.060 reaching 12 months of treatment around year-end, with interim results thereafter. The company also expects to file an IND for ACI-19764 this year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.